180 related articles for article (PubMed ID: 20651054)
41. [Research progress of circulating tumor DNA methylation in non-small cell lung cancer].
Yang Lan L; Chen Bojiang BJ; Li Lei L
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Dec; 41(12):967-970. PubMed ID: 30522195
[No Abstract] [Full Text] [Related]
42. Assessment of the clinical relevance of 17q25.3 copy number and three-dimensional telomere organization in non-small lung cancer patients.
Sunpaweravong P; Thu KL; Lam WL; Mai S
J Cancer Res Clin Oncol; 2016 Apr; 142(4):749-56. PubMed ID: 26621152
[TBL] [Abstract][Full Text] [Related]
43. Surfactant protein A gene deletion and prognostics for patients with stage I non-small cell lung cancer.
Jiang F; Caraway NP; Nebiyou Bekele B; Zhang HZ; Khanna A; Wang H; Li R; Fernandez RL; Zaidi TM; Johnston DA; Katz RL
Clin Cancer Res; 2005 Aug; 11(15):5417-24. PubMed ID: 16061856
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
[TBL] [Abstract][Full Text] [Related]
45. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
[TBL] [Abstract][Full Text] [Related]
46. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P
Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135
[TBL] [Abstract][Full Text] [Related]
47. Use of circulating tumor cells in prospective clinical trials for NSCLC patients - standardization of the pre-analytical conditions.
Ilie M; Hofman V; Leroy S; Cohen C; Heeke S; Cattet F; Bence C; Lalvée S; Mouroux J; Marquette CH; Hofman P;
Clin Chem Lab Med; 2018 May; 56(6):980-989. PubMed ID: 29397019
[TBL] [Abstract][Full Text] [Related]
48. Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer.
Liu Y; Zhang G; Li H; Han L; Fu A; Zhang N; Zheng Y
Biomed Pharmacother; 2015 Oct; 75():185-90. PubMed ID: 26337230
[TBL] [Abstract][Full Text] [Related]
49. Gain of the EGFR gene located on 7p12 is a frequent and early event in squamous cell carcinoma of the lung.
Kang JU; Koo SH; Kwon KC; Park JW; Jung SS
Cancer Genet Cytogenet; 2008 Jul; 184(1):31-7. PubMed ID: 18558286
[TBL] [Abstract][Full Text] [Related]
50. Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients.
Kumar S; Sharawat SK; Ali A; Gaur V; Malik PS; Kumar S; Mohan A; Guleria R
Curr Probl Cancer; 2020 Aug; 44(4):100540. PubMed ID: 32007320
[TBL] [Abstract][Full Text] [Related]
51. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes.
Sher YP; Shih JY; Yang PC; Roffler SR; Chu YW; Wu CW; Yu CL; Peck K
Clin Cancer Res; 2005 Jan; 11(1):173-9. PubMed ID: 15671543
[TBL] [Abstract][Full Text] [Related]
52. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens.
Daniele L; Macrì L; Schena M; Dongiovanni D; Bonello L; Armando E; Ciuffreda L; Bertetto O; Bussolati G; Sapino A
Mol Cancer Ther; 2007 Apr; 6(4):1223-9. PubMed ID: 17406029
[TBL] [Abstract][Full Text] [Related]
53. ROS1 copy number alterations are frequent in non-small cell lung cancer.
Clavé S; Gimeno J; Muñoz-Mármol AM; Vidal J; Reguart N; Carcereny E; Pijuan L; Menéndez S; Taus Á; Mate JL; Serrano S; Albanell J; Espinet B; Arriola E; Salido M
Oncotarget; 2016 Feb; 7(7):8019-28. PubMed ID: 26783962
[TBL] [Abstract][Full Text] [Related]
54. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine.
Sokolova IA; Halling KC; Jenkins RB; Burkhardt HM; Meyer RG; Seelig SA; King W
J Mol Diagn; 2000 Aug; 2(3):116-23. PubMed ID: 11229514
[TBL] [Abstract][Full Text] [Related]
55. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study.
Suzuki S; Dobashi Y; Sakurai H; Nishikawa K; Hanawa M; Ooi A
Cancer; 2005 Mar; 103(6):1265-73. PubMed ID: 15712203
[TBL] [Abstract][Full Text] [Related]
56. Circulating serum exosomal miR-20b-5p and miR-3187-5p as efficient diagnostic biomarkers for early-stage non-small cell lung cancer.
Zhang ZJ; Song XG; Xie L; Wang KY; Tang YY; Yu M; Feng XD; Song XR
Exp Biol Med (Maywood); 2020 Oct; 245(16):1428-1436. PubMed ID: 32741216
[TBL] [Abstract][Full Text] [Related]
57. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
[TBL] [Abstract][Full Text] [Related]
58. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
59. Upregulation of serum miR-494 predicts poor prognosis in non-small cell lung cancer patients.
Zhang J; Wang T; Zhang Y; Wang H; Wu Y; Liu K; Pei C
Cancer Biomark; 2018; 21(4):763-768. PubMed ID: 29286916
[TBL] [Abstract][Full Text] [Related]
60. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
